Management of dyslipidemia in diabetic CKD patients;Prise en charge thérapeutique de la dyslipidémie chez les patients ayant une néphropathie diabétique

Nephrologie et Therapeutique

Volumn 2, Issue SUPPL. 1, 2006, Pages

  Massy, Ziad A ^a   Andréjak, Michel ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Chronic kidney disease; Diabetes; Dyslipidemia; Nephropathy

Indexed keywords

ANTILIPEMIC AGENT; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN SENSITIZING AGENT; LOW DENSITY LIPOPROTEIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SIMVASTATIN; STATINE DERIVATIVE; TRIACYLGLYCEROL;

CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIET THERAPY; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT INDICATION; TREATMENT OUTCOME;

CHRONIC DISEASE; DIABETIC NEPHROPATHIES; DYSLIPIDEMIAS; HUMANS;

EID: 31544464089     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (17)

1. Lacour B, Massy ZA, Jungers P, Drucke T. Anomalies of lipoprotein metabolism in chronic renal insufficiency. Nephrologie 1993;14(2):75-90.
2. Hirano T. Lipoprotein abnormalities in diabetic nephropathy. Kidney Int Suppl 1999 Jul;71:S22-4.
3. Yoshino G, Hirano T, Kazumi T. Atherogenic lipoproteins and diabetes mellitus. J Diabetes Complications 2002;16(1):29-34.
4. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353(3):238-48.
5. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002;13(7):1894-900.
6. Lin SH, Lin YF, Kuo SW, Hsu YJ, Hung YJ. Rosiglitazone improves glucose metabolism in nondiabetic uremic patients on CARD. Am J Kidney Dis 2003;42(4):774-80.
7. Nakamura T, Ushiyama C, Osada S, Shimada N, Ebihara I, Koide H. Effect of pioglitazone on dyslipidemia in hemodialysis patients with type 2 diabetes. Ren. Fail. 2001;23(6):863-4.
8. Lalau JD, Vermersch A, Hary L, Andrejak M, Isnard F, Quichaud J. Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly). Int J Clin Pharmacol Ther Toxicol 1990;28(8):329-32.
9. Gras-Champel V, Munier A, Massy ZA. Controversy regarding the use of metformin in diabetic patients with chronic kidney disease stage 2 and 3. http://www.ndt-educational.org/gras-champelcase.asp.
10. Anonymous. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998;352(9131):854-65.
11. Afssaps. Prise en charge thérapeutique du patient dystipidémique mars 2005. http://agmed.sante.gouv.fr.
12. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361(9374):2005-16.
13. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364(9435):685-96.
14. Garg A. Statins for all patients with type 2 diabetes: not so soon. Lancet 2004;364(9435):641-2.
15. Massy Z. Étude SHARP. Néphrologie 2005;1(3):204-5.
16. Pasternack A, Vanttinen T, Solakivi T, Kuusi T, Korte T. Normalization of lipoprotein lipase and hepatic lipase by gemfibrozil results in correction of lipoprotein abnormalities in chronic renal failure. Clin Nephrol 1987;27(4):163-8.
17. Samuelsson O, Attman PO, Knight-Gibson C, Kron B, Larsson R, Mulec H, Weiss L, Alaupovic P. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease. Nephron 1997;75(3):286-94.